Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulocuplumab - Bristol-Myers Squibb

Next Previous
Drug Profile

Ulocuplumab - Bristol-Myers Squibb

Alternative Names: BMS-936564; MDX-1338

Latest Information Update: 14 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer Bristol-Myers Squibb; Medarex; University of Bari
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Solid tumours; Waldenstrom's macroglobulinaemia
  • No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Multiple myeloma; Neuroectodermal tumours; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 31 Dec 2022 Bristol-Myers Squibb and Dana-Farber Cancer Institute terminates phase I/II trials in Waldenstrom's macroglobulinaemia (Combination therapy) in USA due to sponsor decision to end follow-up early (IV) (NCT03225716)
  • 28 Feb 2021 No recent reports of development identified for preclinical development in Neuroectodermal-tumours in Italy
  • 28 Jan 2021 No recent reports of development identified for phase-I development in Multiple-myeloma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top